Back to top
more

Enanta Pharmaceuticals (ENTA)

(Real Time Quote from BATS)

$13.36 USD

13.36
7,190

+0.45 (3.49%)

Updated May 14, 2024 10:24 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ENTA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Enanta Pharmaceuticals, Inc falls in the month of September.

All items in Millions except Per Share data.

9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019
Assets          
Cash & Equivalents 370 249 244 387 335
Receivables 40 49 61 23 51
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 13 13 14 27 15
Total Current Assets 423 312 319 437 402
Net Property & Equipment 12 6 6 9 11
Investments & Advances 0 29 108 33 65
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 11
Intangibles 0 0 0 0 0
Deposits & Other Assets 5 5 1 1 1
Total Assets 462 375 439 486 490
Liabilities & Shareholders Equity 9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019
Notes Payable 0 0 0 0 0
Accounts Payable 4 6 10 6 7
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 18 21 22 14 16
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 35 0 0 0 0
Total Current Liabilities 63 30 36 24 23
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 160 0 1 1 3
Minority Interest (Liabilities) 1 1 2 1 2
Total Liabilities 246 54 39 31 27
Shareholders Equity 9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 425 398 351 327 298
Retained Earnings -207 -73 49 128 164
Other Equity -1 -4 0 1 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 217 321 399 456 462
Total Liabilities & Shareholder's Equity 462 375 439 486 490
Total Common Equity 217 321 399 456 462
Shares Outstanding 21.00 20.70 20.20 20.00 19.60
Book Value Per Share 10.32 15.52 19.77 22.78 23.60

Fiscal Year End for Enanta Pharmaceuticals, Inc falls in the month of September.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents 300 337 370 387 210
Receivables 40 40 40 45 47
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 11 13 13 17 14
Total Current Assets 351 390 423 448 271
Net Property & Equipment 15 12 12 12 11
Investments & Advances 0 0 0 6 15
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 4 5 5 5 5
Total Assets 414 429 462 495 326
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable 0 0 0 0 0
Accounts Payable 7 9 4 8 12
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 11 12 18 18 15
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 34 37 35 37 0
Total Current Liabilities 55 62 63 68 32
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 148 160 165 0
Minority Interest (Liabilities) 1 1 1 1 1
Total Liabilities 247 237 246 257 57
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 438 433 425 418 411
Retained Earnings -272 -240 -207 -179 -140
Other Equity -1 -1 -1 -2 -2
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 166 192 217 238 269
Total Liabilities & Shareholder's Equity 414 429 462 495 326
Total Common Equity 166 192 217 238 269
Shares Outstanding 21.10 21.10 21.00 21.00 21.00
Book Value Per Share 7.87 9.09 10.32 11.32 12.83